{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:54Z","timestamp":1793946534219,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.diabres.2026.113282","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:58:13Z","timestamp":1777841893000},"page":"113282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin"],"prefix":"10.1016","volume":"236","author":[{"given":"Tien-Phat","family":"Dao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chun","family":"Lung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Min","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tse","family":"Tsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau-Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chao","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113282_b0005","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0020","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with Chronic Kidney Disease","volume":"383","author":"Heerspink Hiddo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0025","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0030","doi-asserted-by":"crossref","unstructured":"The Empa-Kidney Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117-27.","DOI":"10.1056\/NEJMoa2204233"},{"key":"10.1016\/j.diabres.2026.113282_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081820","article-title":"Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial","volume":"388","author":"Liu","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113282_b0040","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue distribution in patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.diabres.2026.113282_b0045","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of Empagliflozin on Blood pressure in patients with Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.diabres.2026.113282_b0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113282_b0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in patients with Type 2 Diabetes: a Meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2026.113282_b0060","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 Inhibitors on Cardiovascular Outcomes across Various Patient Populations","volume":"81","author":"Usman Muhammad","year":"2023","journal-title":"JACC"},{"key":"10.1016\/j.diabres.2026.113282_b0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0070","unstructured":"A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events. 2015."},{"key":"10.1016\/j.diabres.2026.113282_b0075","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with Diabetes and recent Worsening Heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113282_b0090","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjcard.2022.05.005","article-title":"Meta-analysis addressing the Cardiovascular Safety of Bexagliflozin in patients with Type 2 Diabetes Mellitus","volume":"178","author":"Patoulias","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabres.2026.113282_b0095","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/dom.15394","article-title":"Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin","volume":"26","author":"McMurray","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113282_b0100","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/ehf2.15036","article-title":"Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1\/2 inhibitor, for heart failure in type 2 diabetes","volume":"12","author":"Bantounou","year":"2025","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.diabres.2026.113282_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42078","article-title":"Association of Sodium-Glucose Cotransporter 2 Inhibitors with Cardiovascular Outcomes in patients with Type 2 Diabetes and other Risk Factors for Cardiovascular Disease: a Meta-analysis","volume":"5","author":"Bhattarai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2026.113282_b0110","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00392-024-02386-6","article-title":"Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"113","author":"Xu","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.diabres.2026.113282_b0115","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors and Major adverse Cardiovascular Outcomes: a SMART-C Collaborative Meta-Analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2026.113282_b0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13643-025-02766-7","article-title":"Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials","volume":"14","author":"Lin","year":"2025","journal-title":"Syst Rev"},{"key":"10.1016\/j.diabres.2026.113282_b0125","unstructured":"Page MJ HJ, Sterne JAC. Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis. In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 ed: Cochrane; 2024."},{"key":"10.1016\/j.diabres.2026.113282_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22423","article-title":"Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats","volume":"9","author":"Zhong","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.diabres.2026.113282_b0135","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc21-2166","article-title":"Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared with Empagliflozin in patients with Type 2 Diabetes: a Randomized","volume":"45","author":"Posch","year":"2022","journal-title":"Double-Blind Study Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113282_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2337\/cd23-0085","article-title":"Bexagliflozin","volume":"42","author":"Giruzzi","year":"2023","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.diabres.2026.113282_b0145","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/oby.22748","article-title":"Efficacy and Safety of Ertugliflozin in patients with Overweight and Obesity with Type 2 Diabetes Mellitus","volume":"28","author":"Heymsfield","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.diabres.2026.113282_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177784","article-title":"Ertugliflozin induces vasodilation by inhibiting AMPK-mediated mitochondrial fission in vascular smooth muscle cells","volume":"1002","author":"Yan","year":"2025","journal-title":"Eur J Pharmacol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:56:21Z","timestamp":1793944581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S0168822726002020"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113282","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113282"}}